<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="blood"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3501717/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501717/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Blood"><meta name="citation_title" content="Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia"><meta name="citation_authors" content="Jun J. Yang, Cheng Cheng, Meenakshi Devidas, Xueyuan Cao, Dario Campana, Wenjian Yang, Yiping Fan, Geoff Neale, Nancy Cox, Paul Scheet, Michael J. Borowitz, Naomi J. Winick, Paul L. Martin, W. Paul Bowman, Bruce Camitta, Gregory H. Reaman, William L. Carroll, Cheryl L. Willman, Stephen P. Hunger, William E. Evans, Ching-Hon Pui, Mignon Loh, Mary V. Relling"><meta name="citation_date" content="15 November 2012"><meta name="citation_issue" content="20"><meta name="citation_volume" content="120"><meta name="citation_firstpage" content="4197"><meta name="citation_doi" content="10.1182/blood-2012-07-440107"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3501717/?report=abstract"><meta name="citation_pmid" content="23007406"><meta name="DC.Title" content="Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="The American Society of Hematology"><meta name="DC.Contributor" content="Jun J. Yang"><meta name="DC.Contributor" content="Cheng Cheng"><meta name="DC.Contributor" content="Meenakshi Devidas"><meta name="DC.Contributor" content="Xueyuan Cao"><meta name="DC.Contributor" content="Dario Campana"><meta name="DC.Contributor" content="Wenjian Yang"><meta name="DC.Contributor" content="Yiping Fan"><meta name="DC.Contributor" content="Geoff Neale"><meta name="DC.Contributor" content="Nancy Cox"><meta name="DC.Contributor" content="Paul Scheet"><meta name="DC.Contributor" content="Michael J. Borowitz"><meta name="DC.Contributor" content="Naomi J. Winick"><meta name="DC.Contributor" content="Paul L. Martin"><meta name="DC.Contributor" content="W. Paul Bowman"><meta name="DC.Contributor" content="Bruce Camitta"><meta name="DC.Contributor" content="Gregory H. Reaman"><meta name="DC.Contributor" content="William L. Carroll"><meta name="DC.Contributor" content="Cheryl L. Willman"><meta name="DC.Contributor" content="Stephen P. Hunger"><meta name="DC.Contributor" content="William E. Evans"><meta name="DC.Contributor" content="Ching-Hon Pui"><meta name="DC.Contributor" content="Mignon Loh"><meta name="DC.Contributor" content="Mary V. Relling"><meta name="DC.Date" content="2012 Nov 15"><meta name="DC.Identifier" content="10.1182/blood-2012-07-440107"><meta name="DC.Language" content="en"><meta property="og:title" content="Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia"><meta property="og:type" content="article"><meta property="og:description" content="With the use of risk-directed therapy for childhood acute lymphoblastic leukemia (ALL), outcome has improved dramatically in the past 40 years. However, a substantial portion of patients, many of whom have no known risk factors, experience relapse. Taking ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501717/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-blood.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC3501717/epub/">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8C6F0DDD546C410000000006570434.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3501717%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed">PubMed</option><option value="books">Books</option><option value="gquery" class="last">All Databases</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=%22Blood%22[journal]" class="navlink">Blood</a></li><li class="accid">PMC3501717</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-blood.gif" alt="Logo of blood" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="139,56,200,76" alt="Original Article" title="Original Article" href="http://www.bloodjournal.org/content/120/20/4197" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7CArticle%7CFullText" target="pmc_ext"><area shape="rect" coords="0,0,157,57" alt="Blood Journal" title="Blood Journal" href="http://www.bloodjournal.org/" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="200,56,258,76" alt="Current Issue" title="Current Issue" href="http://www.bloodjournal.org/content/current" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="257,56,311,76" alt="About Blood" title="About Blood" href="http://www.bloodjournal.org/page/about-blood" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="309,56,364,77" alt="Submissions" title="Submissions" href="https://submit.bloodjournal.org/" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="363,56,420,78" alt="Subscriptions" title="Subscriptions" href="http://www.bloodjournal.org/page/subscriptions" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="418,56,476,76" alt="Contact Us" title="Contact Us" href="http://bloodjournal.org" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="poly" coords="450,2,431,9,425,27,429,43,437,54,459,55,471,52,483,42,486,29,479,11,466,2,449,2" alt="ASH Homepage" title="ASH Homepage" href="http://www.hematology.org" ref="reftype=publisher&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Blood</a></span>. 2012 Nov 15; 120(20): 4197–4204. </span></div><div><span class="fm-vol-iss-date">Prepublished online 2012 Sep 24. </span>  <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1182%2Fblood-2012-07-440107" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1182/blood-2012-07-440107</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3501717</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/23007406">23007406</a></div></div></div></div><h1 class="content-title">Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Yang%20JJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719321829360" co-class="co-affbox">Jun J. Yang</a>,<sup>1</sup> <a href="/pubmed/?term=Cheng%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719306307712" co-class="co-affbox">Cheng Cheng</a>,<sup>2</sup> <a href="/pubmed/?term=Devidas%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719321827376" co-class="co-affbox">Meenakshi Devidas</a>,<sup>3</sup> <a href="/pubmed/?term=Cao%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719300963840" co-class="co-affbox">Xueyuan Cao</a>,<sup>2</sup> <a href="/pubmed/?term=Campana%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719300961856" co-class="co-affbox">Dario Campana</a>,<sup>4</sup> <a href="/pubmed/?term=Yang%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719321686160" co-class="co-affbox">Wenjian Yang</a>,<sup>1</sup> <a href="/pubmed/?term=Fan%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719315713424" co-class="co-affbox">Yiping Fan</a>,<sup>5</sup> <a href="/pubmed/?term=Neale%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719323724256" co-class="co-affbox">Geoff Neale</a>,<sup>5</sup> <a href="/pubmed/?term=Cox%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719323722272" co-class="co-affbox">Nancy Cox</a>,<sup>6</sup> <a href="/pubmed/?term=Scheet%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719306496608" co-class="co-affbox">Paul Scheet</a>,<sup>7</sup> <a href="/pubmed/?term=Borowitz%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719311011728" co-class="co-affbox">Michael J. Borowitz</a>,<sup>8</sup> <a href="/pubmed/?term=Winick%20NJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719311009744" co-class="co-affbox">Naomi J. Winick</a>,<sup>9</sup> <a href="/pubmed/?term=Martin%20PL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719315096832" co-class="co-affbox">Paul L. Martin</a>,<sup>10</sup> <a href="/pubmed/?term=Bowman%20WP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719316313536" co-class="co-affbox">W. Paul Bowman</a>,<sup>11</sup> <a href="/pubmed/?term=Camitta%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719316311552" co-class="co-affbox">Bruce Camitta</a>,<sup>12</sup> <a href="/pubmed/?term=Reaman%20GH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719297436656" co-class="co-affbox">Gregory H. Reaman</a>,<sup>13</sup> <a href="/pubmed/?term=Carroll%20WL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719306140816" co-class="co-affbox">William L. Carroll</a>,<sup>14</sup> <a href="/pubmed/?term=Willman%20CL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719306138832" co-class="co-affbox">Cheryl L. Willman</a>,<sup>15</sup> <a href="/pubmed/?term=Hunger%20SP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719311945456" co-class="co-affbox">Stephen P. Hunger</a>,<sup>16</sup> <a href="/pubmed/?term=Evans%20WE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719306589472" co-class="co-affbox">William E. Evans</a>,<sup>1</sup> <a href="/pubmed/?term=Pui%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719394741328" co-class="co-affbox">Ching-Hon Pui</a>,<sup>4</sup> <a href="/pubmed/?term=Loh%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719394739344" co-class="co-affbox">Mignon Loh</a>,<sup>17</sup> and  <a href="/pubmed/?term=Relling%20MV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406" class="affpopup" co-rid="_co_idm140719319444896" co-class="co-affbox">Mary V. Relling</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author"></sup><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140719321829360"><h3 class="no_margin">Jun J. Yang</h3><p><sup>1</sup>Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Yang%20JJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Jun J. Yang</a></div></div><div id="_co_idm140719306307712"><h3 class="no_margin">Cheng Cheng</h3><p><sup>2</sup>Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Cheng%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Cheng Cheng</a></div></div><div id="_co_idm140719321827376"><h3 class="no_margin">Meenakshi Devidas</h3><p><sup>3</sup>Department of Epidemiology and Health Policy Research, University of Florida, Gainesville, FL; </p><div>Find articles by <a href="/pubmed/?term=Devidas%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Meenakshi Devidas</a></div></div><div id="_co_idm140719300963840"><h3 class="no_margin">Xueyuan Cao</h3><p><sup>2</sup>Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Cao%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Xueyuan Cao</a></div></div><div id="_co_idm140719300961856"><h3 class="no_margin">Dario Campana</h3><p><sup>4</sup>Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Campana%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Dario Campana</a></div></div><div id="_co_idm140719321686160"><h3 class="no_margin">Wenjian Yang</h3><p><sup>1</sup>Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Yang%20W%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Wenjian Yang</a></div></div><div id="_co_idm140719315713424"><h3 class="no_margin">Yiping Fan</h3><p><sup>5</sup>Hartwell Biotechnology Center, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Fan%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Yiping Fan</a></div></div><div id="_co_idm140719323724256"><h3 class="no_margin">Geoff Neale</h3><p><sup>5</sup>Hartwell Biotechnology Center, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Neale%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Geoff Neale</a></div></div><div id="_co_idm140719323722272"><h3 class="no_margin">Nancy Cox</h3><p><sup>6</sup>Department of Medicine, University of Chicago, Chicago, IL; </p><div>Find articles by <a href="/pubmed/?term=Cox%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Nancy Cox</a></div></div><div id="_co_idm140719306496608"><h3 class="no_margin">Paul Scheet</h3><p><sup>7</sup>Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX; </p><div>Find articles by <a href="/pubmed/?term=Scheet%20P%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Paul Scheet</a></div></div><div id="_co_idm140719311011728"><h3 class="no_margin">Michael J. Borowitz</h3><p><sup>8</sup>Johns Hopkins Medical Institute, Baltimore, MD; </p><div>Find articles by <a href="/pubmed/?term=Borowitz%20MJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Michael J. Borowitz</a></div></div><div id="_co_idm140719311009744"><h3 class="no_margin">Naomi J. Winick</h3><p><sup>9</sup>Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX; </p><div>Find articles by <a href="/pubmed/?term=Winick%20NJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Naomi J. Winick</a></div></div><div id="_co_idm140719315096832"><h3 class="no_margin">Paul L. Martin</h3><p><sup>10</sup>Department of Pediatrics, Duke University, Durham, NC; </p><div>Find articles by <a href="/pubmed/?term=Martin%20PL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Paul L. Martin</a></div></div><div id="_co_idm140719316313536"><h3 class="no_margin">W. Paul Bowman</h3><p><sup>11</sup>Cook Children's Medical Center, Ft Worth, TX; </p><div>Find articles by <a href="/pubmed/?term=Bowman%20WP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">W. Paul Bowman</a></div></div><div id="_co_idm140719316311552"><h3 class="no_margin">Bruce Camitta</h3><p><sup>12</sup>Medical College of Wisconsin, Milwaukee, WI; </p><div>Find articles by <a href="/pubmed/?term=Camitta%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Bruce Camitta</a></div></div><div id="_co_idm140719297436656"><h3 class="no_margin">Gregory H. Reaman</h3><p><sup>13</sup>George Washington University, Children's National Medical Center, Washington, DC; </p><div>Find articles by <a href="/pubmed/?term=Reaman%20GH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Gregory H. Reaman</a></div></div><div id="_co_idm140719306140816"><h3 class="no_margin">William L. Carroll</h3><p><sup>14</sup>New York University Cancer Institute, New York, NY; </p><div>Find articles by <a href="/pubmed/?term=Carroll%20WL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">William L. Carroll</a></div></div><div id="_co_idm140719306138832"><h3 class="no_margin">Cheryl L. Willman</h3><p><sup>15</sup>University of New Mexico Cancer Center, Albuquerque, NM; </p><div>Find articles by <a href="/pubmed/?term=Willman%20CL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Cheryl L. Willman</a></div></div><div id="_co_idm140719311945456"><h3 class="no_margin">Stephen P. Hunger</h3><p><sup>16</sup>University of Colorado School of Medicine and The Children's Hospital, Aurora, CO; and </p><div>Find articles by <a href="/pubmed/?term=Hunger%20SP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Stephen P. Hunger</a></div></div><div id="_co_idm140719306589472"><h3 class="no_margin">William E. Evans</h3><p><sup>1</sup>Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Evans%20WE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">William E. Evans</a></div></div><div id="_co_idm140719394741328"><h3 class="no_margin">Ching-Hon Pui</h3><p><sup>4</sup>Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Pui%20CH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Ching-Hon Pui</a></div></div><div id="_co_idm140719394739344"><h3 class="no_margin">Mignon Loh</h3><p><sup>17</sup>Department of Pediatrics, University of California, San Francisco, San Francisco, CA</p><div>Find articles by <a href="/pubmed/?term=Loh%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Mignon Loh</a></div></div><div id="_co_idm140719319444896"><h3 class="no_margin">Mary V. Relling</h3><p><sup>1</sup>Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN; </p><div>Find articles by <a href="/pubmed/?term=Relling%20MV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23007406">Mary V. Relling</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140719296809584_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140719296809584_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140719296809584_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140719296809584_ai" style="display:none"><div class="fm-affl" id="aff1" lang="en"><sup>1</sup>Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN; </div><div class="fm-affl" id="aff2" lang="en"><sup>2</sup>Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; </div><div class="fm-affl" id="aff3" lang="en"><sup>3</sup>Department of Epidemiology and Health Policy Research, University of Florida, Gainesville, FL; </div><div class="fm-affl" id="aff4" lang="en"><sup>4</sup>Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; </div><div class="fm-affl" id="aff5" lang="en"><sup>5</sup>Hartwell Biotechnology Center, St Jude Children's Research Hospital, Memphis, TN; </div><div class="fm-affl" id="aff6" lang="en"><sup>6</sup>Department of Medicine, University of Chicago, Chicago, IL; </div><div class="fm-affl" id="aff7" lang="en"><sup>7</sup>Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX; </div><div class="fm-affl" id="aff8" lang="en"><sup>8</sup>Johns Hopkins Medical Institute, Baltimore, MD; </div><div class="fm-affl" id="aff9" lang="en"><sup>9</sup>Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX; </div><div class="fm-affl" id="aff10" lang="en"><sup>10</sup>Department of Pediatrics, Duke University, Durham, NC; </div><div class="fm-affl" id="aff11" lang="en"><sup>11</sup>Cook Children's Medical Center, Ft Worth, TX; </div><div class="fm-affl" id="aff12" lang="en"><sup>12</sup>Medical College of Wisconsin, Milwaukee, WI; </div><div class="fm-affl" id="aff13" lang="en"><sup>13</sup>George Washington University, Children's National Medical Center, Washington, DC; </div><div class="fm-affl" id="aff14" lang="en"><sup>14</sup>New York University Cancer Institute, New York, NY; </div><div class="fm-affl" id="aff15" lang="en"><sup>15</sup>University of New Mexico Cancer Center, Albuquerque, NM; </div><div class="fm-affl" id="aff16" lang="en"><sup>16</sup>University of Colorado School of Medicine and The Children's Hospital, Aurora, CO; and </div><div class="fm-affl" id="aff17" lang="en"><sup>17</sup>Department of Pediatrics, University of California, San Francisco, San Francisco, CA</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author"></sup>Corresponding author.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm140719296809584_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2012 Jul 1; Accepted 2012 Sep 14.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm140719296809584_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> © 2012 by The American Society of Hematology</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC3501717/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">
Supplemental Tables and Figures
</div>

<div><a href="/pmc/articles/PMC3501717/bin/supp_120_20_4197__index.html" data-ga-action="click_feat_suppl">supp_120_20_4197__index.html</a><span style="color:gray"> (1.0K)</span></div><div class="small guid">GUID:&nbsp;240E7536-BE4D-435C-AE3A-005CD2D322AF</div>
<div><a href="/pmc/articles/PMC3501717/bin/supp_blood-2012-07-440107_blood-2012-07-440107-1.pdf" data-ga-action="click_feat_suppl">supp_blood-2012-07-440107_blood-2012-07-440107-1.pdf</a><span style="color:gray"> (677K)</span></div><div class="small guid">GUID:&nbsp;69817B3B-C37D-4CA8-9593-3FADD47110F7</div>
</div></dd></dl></div><div id="idm140719317264656" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140719317264656title">Abstract</h2><!--article-meta--><div><p id="__p1" class="p p-first-last">With the use of risk-directed therapy for childhood acute lymphoblastic leukemia (ALL), outcome has improved dramatically in the past 40 years. However, a substantial portion of patients, many of whom have no known risk factors, experience relapse. Taking a genome-wide approach, in the present study, we evaluated the relationships between genotypes at 444 044 single nucleotide polymorphisms (SNPs) with the risk of relapse in 2535 children with newly diagnosed ALL after adjusting for genetic ancestry and treatment regimen. We identified 134 SNPs that were reproducibly associated with ALL relapse. Of 134 relapse SNPs, 133 remained prognostic after adjusting for all known relapse risk factors, including minimal residual disease, and 111 were significant even among patients who were negative for minimal residual disease after remission induction therapy. The C allele at rs7142143 in the <em>PYGL</em> gene was associated with 3.6-fold higher risk of relapse than the T allele (<em>P</em> = 6.7 × 10<sup>−9</sup>). Fourteen of the 134 relapse SNPs, including variants in <em>PDE4B</em> and <em>ABCB1</em>, were also associated with antileukemic drug pharmacokinetics and/or pharmacodynamics. In the present study, we systematically identified host genetic variations related to treatment outcome of childhood ALL, most of which were prognostic independent of known risk factors for relapse, and some of which also influenced outcome by affecting host dis-position of antileukemic drugs. All trials are registered at <a href="http://www.clinicaltrials.gov" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">www.clinicaltrials.gov</a> or <a href="http://www.cancer.gov" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">www.cancer.gov</a> (COG P9904: <a id="__tag_556331344" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00005585" ref="reftype=extlink-clinical-trial&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00005585","term_id":"NCT00005585"}}</span>NCT00005585</a>; COG P9905: <a id="__tag_556331342" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00005596" ref="reftype=extlink-clinical-trial&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00005596","term_id":"NCT00005596"}}</span>NCT00005596</a>; COG P9906: <a id="__tag_556331343" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00005603" ref="reftype=extlink-clinical-trial&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00005603","term_id":"NCT00005603"}}</span>NCT00005603</a>; St Jude Total XIIIB: NCI-T93-0101D; and St Jude Total XV: <a id="__tag_556331345" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00137111" ref="reftype=extlink-clinical-trial&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00137111","term_id":"NCT00137111"}}</span>NCT00137111</a>).</p></div></div><div id="__sec1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec1title">Introduction</h2><p id="__p2" class="p p-first">In childhood acute lymphoblastic leukemia (ALL), risk-adapted combination therapy has led to dramatic improvements in outcome, with 5-year survival rates of more than 85% in most industrialized countries.<sup><a href="#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115583">1</a></sup> However, ALL relapse still carries a very poor prognosis and the majority of relapses continue to occur in patients without apparent “high-risk” features.<sup><a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115589">2</a><a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115567"></a>–<a href="#B4" rid="B4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115592">4</a></sup> Therefore, more accurate risk classification of newly diagnosed disease is needed to reduce relapses and improve the overall outcome of ALL.</p><p id="__p3">Prior efforts to improve risk stratification primarily focused on genetic variations of the tumor or on assessment of early antileukemic response; for example, the upfront prednisone response<sup><a href="#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115562">5</a></sup> and minimal residual disease (MRD) after remission induction.<sup><a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115552">6</a></sup> The role of inherited genetic variations on treatment response in children with ALL has received increasing attention.<sup><a href="#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115549">7</a></sup> For example, candidate gene studies have suggested that genetic polymorphisms in metabolizing enzymes (<em>GSTM1</em>) and transporters (<em>ABCC4</em>) of antileukemic agents affect treatment outcome.<sup><a href="#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115557">8</a>,<a href="#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115570">9</a></sup> Recent studies have also identified associations between sequence variations in cytokine and chemokine genes and early treatment response,<sup><a href="#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115541">7</a>,<a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115558">10</a></sup> indicating tumor-microenvironment interaction as one plausible mechanism by which host genetic variations affect ALL outcome.<sup><a href="#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115586">11</a></sup></p><p id="__p4" class="p p-last">Prognostic features of ALL are strongly dependent on treatment, and the lack of “replication” of pharmacogenetic findings in chemotherapy trials (and particularly outside of the context of clinical trials) may be attributed to modest differences in therapy among trials. To maximize the opportunity of identifying genotype-phenotype associations generalizable to diverse treatment regimens, in the present study, we applied an iterative “discovery versus replication” genomic screen to a core panel of frontline ALL trials in the Children's Oncology Group (COG) and at St Jude Children's Research Hospital. Our goal was to agnostically test single nucleotide polymorphisms (SNPs) throughout the genome for their association with the risk of relapse in a large group of children with ALL (N = 2535) from diverse racial/ethnic backgrounds.</p></div><div id="__sec2" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec2title">Methods</h2><div id="__sec3" class="sec sec-first"><h3 id="__sec3title">Patients and treatment</h3><p id="__p5" class="p p-first">Germline DNA samples were collected at remission in children with newly diagnosed ALL treated on St Jude Children's Research Hospital Total Therapy XIIIB<sup><a href="#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115581">12</a></sup> and XV<sup><a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115546">13</a></sup> or the COG P9906<sup><a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115575">14</a></sup> or COG P9904/P9905 studies<sup><a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115579">14</a></sup> (<a href="/pmc/articles/PMC3501717/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The studies were approved by the institutional review boards and informed consent was obtained from the parents, the guardians, or the patients in accordance with the Declaration of Helsinki. ALL treatment regimens were as described for the St Jude<sup><a href="#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115565">12</a>,<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115556">13</a></sup> and COG<sup><a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115593">14</a></sup> protocols.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p6">Patient characteristics</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719316211216" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1" align="center">N</th><th rowspan="1" colspan="1" align="center">5-y incidence of relapse in % (SD)<sup>¶</sup></th><th rowspan="1" colspan="1" align="center"><em>P</em> value for association with ALL relapse</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left"><strong>Treatment protocol</strong></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1.35 × 10<sup>−14</sup><sup>#</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">    COG P9904/9905</td><td rowspan="1" colspan="1" align="center">1606</td><td rowspan="1" colspan="1" align="center">14.4 (0.89)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    COG P9906</td><td rowspan="1" colspan="1" align="center">222</td><td rowspan="1" colspan="1" align="center">33.5 (3.22)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    St Jude Total Therapy XIIIB</td><td rowspan="1" colspan="1" align="center">222</td><td rowspan="1" colspan="1" align="center">12.2 (2.21)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    St Jude Total Therapy XV</td><td rowspan="1" colspan="1" align="center">485</td><td rowspan="1" colspan="1" align="center">8.97 (1.35)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>Self-reported race/ethnicity</strong><sup>*</sup></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.0052</td></tr><tr><td rowspan="1" colspan="1" align="left">    Asian</td><td rowspan="1" colspan="1" align="center">76</td><td rowspan="1" colspan="1" align="center">20.8 (4.85)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Black</td><td rowspan="1" colspan="1" align="center">251</td><td rowspan="1" colspan="1" align="center">15.1 (2.29)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Hispanic</td><td rowspan="1" colspan="1" align="center">405</td><td rowspan="1" colspan="1" align="center">20.7 (2.05)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Others</td><td rowspan="1" colspan="1" align="center">116</td><td rowspan="1" colspan="1" align="center">17.0 (3.58)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    White</td><td rowspan="1" colspan="1" align="center">1687</td><td rowspan="1" colspan="1" align="center">13.1 (0.84)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>Sex</strong></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.0094</td></tr><tr><td rowspan="1" colspan="1" align="left">    Female</td><td rowspan="1" colspan="1" align="center">1163</td><td rowspan="1" colspan="1" align="center">13.1 (1.01)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Male</td><td rowspan="1" colspan="1" align="center">1372</td><td rowspan="1" colspan="1" align="center">16.4 (1.02)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>Age at diagnosis, y</strong></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">2.37 × 10<sup>−9</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">    &lt; 10</td><td rowspan="1" colspan="1" align="center">1998</td><td rowspan="1" colspan="1" align="center">12.7 (0.76)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    ≥ 10</td><td rowspan="1" colspan="1" align="center">537</td><td rowspan="1" colspan="1" align="center">23.4 (1.87)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>Leukocyte count at diagnosis,/μL</strong></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1.11 × 10<sup>−10</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">    &lt; 50 000</td><td rowspan="1" colspan="1" align="center">2104</td><td rowspan="1" colspan="1" align="center">12.9 (0.75)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    ≥ 50 000</td><td rowspan="1" colspan="1" align="center">431</td><td rowspan="1" colspan="1" align="center">24.8 (2.11)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>CNS status</strong><sup>†</sup></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">.56</td></tr><tr><td rowspan="1" colspan="1" align="left">    CNS3 or traumatic</td><td rowspan="1" colspan="1" align="center">86</td><td rowspan="1" colspan="1" align="center">17.0 (4.21)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    CNS1</td><td rowspan="1" colspan="1" align="center">2124</td><td rowspan="1" colspan="1" align="center">14.4 (0.78)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    CNS2</td><td rowspan="1" colspan="1" align="center">324</td><td rowspan="1" colspan="1" align="center">17.8 (2.17)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Missing</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">0 (0)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>Lineage and molecular subtype of ALL</strong></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1.16 × 10<sup>−6</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">    B-other</td><td rowspan="1" colspan="1" align="center">1673</td><td rowspan="1" colspan="1" align="center">16.0 (0.92)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    <em>BCR-ABL</em></td><td rowspan="1" colspan="1" align="center">14</td><td rowspan="1" colspan="1" align="center">53.6 (15.77)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    <em>TCF3-PBX1</em></td><td rowspan="1" colspan="1" align="center">126</td><td rowspan="1" colspan="1" align="center">16.1 (3.3)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    MLL rearrangement</td><td rowspan="1" colspan="1" align="center">29</td><td rowspan="1" colspan="1" align="center">31.2 (8.83)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    T cell</td><td rowspan="1" colspan="1" align="center">109</td><td rowspan="1" colspan="1" align="center">19.5 (3.85)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    <em>ETV6-RUNX1</em></td><td rowspan="1" colspan="1" align="center">584</td><td rowspan="1" colspan="1" align="center">9 (1.2)</td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>DNA index</strong><sup>‡</sup></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1.04 × 10<sup>−5</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">    &lt; 1.16</td><td rowspan="1" colspan="1" align="center">1798</td><td rowspan="1" colspan="1" align="center">16.7 (0.9)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    ≥ 1.16</td><td rowspan="1" colspan="1" align="center">682</td><td rowspan="1" colspan="1" align="center">10.6 (1.21)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Missing</td><td rowspan="1" colspan="1" align="center">55</td><td rowspan="1" colspan="1" align="center">9.1 (3.93)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left"><strong>End-of-induction MRD</strong><sup>§</sup></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1 × 10<sup>−16</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">    &lt; 0.01%</td><td rowspan="1" colspan="1" align="center">1835</td><td rowspan="1" colspan="1" align="center">10.1 (0.72)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    ≥ 0.01% &amp; &lt; 1%</td><td rowspan="1" colspan="1" align="center">373</td><td rowspan="1" colspan="1" align="center">30.9 (2.45)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    ≥ 1%</td><td rowspan="1" colspan="1" align="center">81</td><td rowspan="1" colspan="1" align="center">59.8 (5.89)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1" align="left">    Missing</td><td rowspan="1" colspan="1" align="center">246</td><td rowspan="1" colspan="1" align="center">12.5 (2.13)</td><td rowspan="1" colspan="1"></td></tr></tbody></table></div><div id="largeobj_idm140719316211216" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3501717/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TF1-1"><sup>*</sup>Self-reported race/ethnicity was assigned based on clinical trial databases.</div><div id="TF1-2"><sup>†</sup>CNS status indicates the level of leukemia in the CNS at diagnosis.</div><div id="TF1-3"><sup>‡</sup>DNA index represents the ratio of DNA content of leukemia sample per diploid human normal control, an indicator of aneuploidy in tumors.</div><div id="TF1-4"><sup>§</sup>MRD was determined at day 29 in the COG cohorts and at day 46 in the St Jude cohorts, as described in “Association of SNPs with additional prognostic phenotypes.”</div><div id="TF1-5"><sup>¶</sup>Relapse is defined as leukemia recurrence in bone marrow and/or extramedullary tissues.</div><div id="TF1-6"><sup>#</sup>Association between patient characteristics and relapse risk was determined using the Gray test in univariate analyses.</div></div></div></div><div id="__sec4" class="sec"><h3 id="__sec4title">Genotyping and genetic ancestry</h3><p id="__p13" class="p p-first">Genotyping and quality control were performed as described previously. Briefly, germline DNA was genotyped using either the Affymetrix GeneChip human Mapping 500K sets or SNP6.0 array. Genotyping calls were determined using the BRLMM<sup><a href="#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115542">15</a></sup> or the Birdseed algorithms<sup><a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115566">16</a></sup> for the 500K array and the SNP6.0 array, respectively. Genotypes were coded assuming an additive genetic model (based on the number of B alleles). Only SNPs common to both Affymetrix array platforms were investigated in this study. We also excluded 26 303 SNPs because of low minor allele frequency (&lt; 0.5%) or poor call rate (&lt; 95%), and 136 patients because of poor genotyping (call rate &lt; 95%).</p><p id="__p14" class="p p-last">European, African, Asian, and Native-American genetic ancestries were estimated using STRUCTURE,<sup><a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115594">17</a></sup> with HapMap CEU, YRI, CHB/JPT, and a cohort of Native Americans<sup><a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115561">18</a></sup> as reference ancestral populations.</p></div><div id="__sec5" class="sec"><h3 id="__sec5title">GWAS for germline SNP genotypes related to risk of relapse</h3><p id="__p15" class="p p-first">For this genome-wide association study (GWAS), relapse was defined as disease recurrence in bone marrow and/or extramedullary sites. Lineage switch, second malignancy, and death in remission were incorporated in the analyses as competing events. All genotype-relapse association analyses were stratified by 9 risk-adapted treatment arms: St Jude Total XIIIB low risk,<sup><a href="#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115571">12</a></sup> St Jude Total XIIIB high risk,<sup><a href="#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115559">12</a></sup> St Jude Total XV low risk,<sup><a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115580">13</a></sup> St Jude Total XV standard/high risk,<sup><a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115554">13</a></sup> COG P9906, and COG P9904/9905 regimens A, B, C, and D.<sup><a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115564">14</a></sup> Known risk factors (leukocyte count [≥ vs &lt; 50 000/μL [age ≥ vs &lt; 10 years], and the presence or absence of molecular ALL subtypes [including <em>MLL</em> rearrangements; <em>ETV6-RUNX1</em>, <em>TCF3-PBX1</em>, or <em>BCR-ABL1</em>; DNA index [≥ vs &lt; 1.16]; and MRD [negative, positive, and high positive as defined below]) were included in the multivariate analysis together with SNP genotype.</p><p id="__p16" class="p p-last">To maximize the statistical power for detecting associations between SNP genotype and relapse risk, we performed a GWAS inclusive of all 2535 patients. SNPs were individually tested for association with relapse using a 2-step procedure. First, the Gray test (stratifying on treatment arms) was applied to each SNP and, second, those SNPs achieving <em>P</em> &lt; .05 were subsequently analyzed using the Fine and Gray hazard rate regression model<sup><a href="#B19" rid="B19" class=" bibr popnode">19</a></sup> including both genetic ancestry (European, African, Asian, and Native American) and treatment arm as covariates, and genotypes were treated as ordinal variables under an additive genetic model. To balance false-positive and false-negative error rates, we examined the profile information criteria<sup><a href="#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_304606956">20</a></sup> and determined that the <em>P</em> value threshold was 4.4 × 10<sup>−3</sup> to declare SNPs significantly related to relapse hazard. To further prioritize the top relapse SNPs, we applied an iterative resampling procedure to determine whether a SNP was reproducibly associated with relapse (<a href="/pmc/articles/PMC3501717/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>). We first split 2535 patients at a 1:1 ratio into a discovery and a replication cohort, balancing on treatment arm, genetic ancestry, CNS disease status, and treatment outcome. SNPs were individually tested in the discovery cohort for association with relapse by the 2-step procedure (Gray test followed by the Fine and Gray hazard regression model) as described in this paragraph. Significant SNPs (at <em>P</em> &lt; 4.4 × 10<sup>−3</sup>) from the discovery cohort GWAS were tested for replication. In the replication cohort, a SNP was considered validated if its genotype was associated with relapse at the 0.05 significance level by both the Gray test and the hazard rate regression model. This discovery-replication procedure was repeated 100 times (<a href="/pmc/articles/PMC3501717/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>), with each of iterations generating a list of replicated SNPs. Those SNPs that were replicated at least 10 times exceeded the frequency that would be expected by chance (<em>P</em> = .028 by the binomial model [100, 0.05]) and were designated as “relapse SNPs.” These SNPs were selected for further analyses with additional phenotypes.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC3501717/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719324471008" class="figure"><a href="/pmc/articles/PMC3501717/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3501717_zh89991299130001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zh89991299130001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3501717/bin/zh89991299130001.jpg"></a></div><div id="largeobj_idm140719324471008" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3501717/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC3501717/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p22"><strong>Iterative resampling approach to identify 134 SNPs reproducibly associated with ALL relapse.</strong> A total of 2535 children with newly diagnosed ALL were split into a discovery and a validation cohort at a 1:1 ratio with balanced representation of treatment and clinical features. GWAS was performed on the discovery cohort and then on filtered SNPs based on replication in the remaining patients (replication cohort). Resampling was performed for 100 iterations and 134 SNPs were selected as “relapse SNPs” because they were successfully replicated in multiple rounds of resampling. Ip indicates information profiling (see “GWAS for germline SNP genotypes related to risk of relapse”).</p></div></div></div></div><div id="__sec6" class="sec"><h3 id="__sec6title">Association of relapse SNPs with additional prognostic phenotypes</h3><div id="__sec7" class="sec sec-first"><p></p><h4 id="__sec7title" class="inline">Clinical presenting features. </h4><p id="__p17" class="p p-first-last">Patient characteristics at diagnosis have been associated with relapse risk. In the present study, we assessed whether genotypes associated with relapse were also related to these prognostic patient characteristics. For each of 134 relapse SNPs, we tested the association between genotype and presenting leukocyte count ≥ versus &lt; 50 000/μL, age ≥ versus &lt; 10 years, and ALL blast DNA index ≥ versus &lt; 1.16 by Fisher test. The association between SNP genotypes and molecular ALL subtypes (<em>MLL</em> rearrangements, <em>ETV6-RUNX1</em>, <em>TCF3-PBX1</em>, or <em>BCR-ABL1</em>, or T-ALL) was tested using the χ<sup>2</sup> test.</p></div><div id="__sec8" class="sec"><p></p><h4 id="__sec8title" class="inline">MRD. </h4><p id="__p18" class="p p-first-last">Of 2535 patients included in the GWAS of relapse, MRD status was available at the end of remission induction therapy (day 28 in the COG studies and day 46 in the St Jude studies) in 2289 children. MRD was measured by flow cytometry and classified as negative (&lt; 0.01%), positive (≥ 0.01% but &lt; 1%), or high-positive (≥ 1%) for St Jude patients. In COG patients, the MRD classification was nearly identical: negative (≤ 0.01%), positive (&gt; 0.01% but ≤ 1%), or high-positive (&gt; 1%). The Spearman rank correlation test was used to determine the association between genotypes and MRD, both of which were treated as ordinal variables.</p></div><div id="__sec9" class="sec sec-last"><p></p><h4 id="__sec9title" class="inline">Antileukemic drug disposition. </h4><p id="__p19" class="p p-first-last">SNPs that have been previously associated with 4 pharmacokinetic and pharmacodynamic phenotypes were analyzed for their overlap with relapse SNPs in the present analyses. These SNPs were identified in GWASs from a subset of patients enrolled on St Jude Total Therapy XIIIB and XV protocols. Methotrexate plasma clearance was assessed in 699 children with ALL,<sup><a href="#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115550">21</a></sup> and the GWAS adjusted for ancestry, dosage schedule, and sex. Those SNPs with <em>P</em> &lt; .05 for their association with clearance were assessed for overlap with SNPs associated with relapse. Intracellular methotrexate polyglutamate accumulation in ALL blasts at 44 hours after upfront methotrexate therapy was determined in 144 newly diagnosed patients who received preinduction therapy with IV methotrexate.<sup><a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115577">22</a></sup> Those SNPs with <em>P</em> &lt; .05 for their association with methotrexate polyglutamates (adjusting for subtype, ancestry, and treatment) were assessed for overlap with relapse SNPs. Dexamethasone apparent oral plasma clearance was determined in 334 patients at week 7 of continuation therapy<sup><a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115563">23</a></sup>; those SNPs with <em>P</em> &lt; .05 for their association with apparent oral clearance (adjusting for age, ancestry, and treatment arm) were assessed for overlap with relapse SNPs. Asparaginase antibody levels were measured in 403 patients using ELISA serially during therapy, and the total cumulative asparaginase Ab area under the curve was estimated<sup><a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115584">23</a></sup>; those SNPs with <em>P</em> &lt; .05 for their association with Ab exposure were assessed for overlap with SNPs associated with relapse. Associations between genotype and all 4 pharmacokinetic phenotypes were evaluated by linear regression tests.</p></div></div><div id="__sec10" class="sec sec-last"><h3 id="__sec10title">Statistical analysis</h3><p id="__p20" class="p p-first-last">Statistical and computational analyses were performed using “R” Version 2.9.1 software (<a href="http://www.r-project.org" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">www.r-project.org</a>) and SAS Version 9.2 software.</p></div></div><div id="__sec11" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec11title">Results</h2><div id="__sec12" class="sec sec-first"><h3 id="__sec12title">Identification of genomic loci associated with ALL relapse risk</h3><p id="__p21" class="p p-first">Using an iterative resampling strategy, we investigated which of the 444 044 germline SNP genotypes were reproducibly associated with relapse across treatment regimens (<a href="/pmc/articles/PMC3501717/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>). Dividing the 2535 patients into a discovery and a replication cohort at a 1:1 ratio, we used the discovery cohort to perform a genome-wide screen and then filtered SNPs based on their association in the replication cohort (<a href="/pmc/articles/PMC3501717/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>). A total of 134 SNPs were successfully replicated in at least 10 of 100 rounds of discovery-replication tests (the top 25 SNPs are shown in <a href="/pmc/articles/PMC3501717/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> and a full listing is provided in supplemental Table 1, available on the <em>Blood</em> Web site; see the Supplemental Materials link at the top of the online article). These 134 SNPs, representing 88 independent genomic loci (pairwise <em>r</em><sup>2</sup> &lt; 0.5, supplemental Figure 1), were also significant in a GWAS inclusive of all 2535 patients (<em>P</em> &lt; .004) and thus were prioritized for subsequent analyses. A total of 73 of 134 SNPs were annotated to 43 genes (within 10 kb of a gene), all of which were intronic except for a synonymous coding variant in the <em>ATP8A2</em> gene (rs6491066).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p23">Top 25 SNPs associated with ALL relapse identified through genome-wide association and multiple rounds of resampling</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719301324576" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th colspan="4" rowspan="1" align="left">SNP information<hr></th><th colspan="5" rowspan="1" align="center">Association with ALL relapse in GWAS<hr></th><th colspan="2" rowspan="1" align="center"><em>P</em> value for independent prognostic value<hr></th></tr><tr><th rowspan="1" colspan="1" align="center">SNP ID</th><th rowspan="1" colspan="1" align="center">Chr</th><th rowspan="1" colspan="1" align="center">Position</th><th rowspan="1" colspan="1" align="center">Gene</th><th rowspan="1" colspan="1" align="center">Risk allele frequency</th><th rowspan="1" colspan="1" align="center">Risk allele</th><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center">HR (95% CI)</th><th rowspan="1" colspan="1" align="center">Validation frequency</th><th rowspan="1" colspan="1" align="center">Adjusting for known risk factors</th><th rowspan="1" colspan="1" align="center">Within MRD<sup>−</sup> patients</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left">rs7142143</td><td rowspan="1" colspan="1" align="center">14</td><td rowspan="1" colspan="1" align="center">50473281</td><td rowspan="1" colspan="1" align="center"><em>PYGL</em></td><td rowspan="1" colspan="1" align="center">1%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">6.72 × 10<sup>−9</sup></td><td rowspan="1" colspan="1" align="center">3.61 (2.34-5.57)</td><td rowspan="1" colspan="1" align="center">79%</td><td rowspan="1" colspan="1" align="center">1.20 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">2.9 × 10<sup>−4</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs17079534</td><td rowspan="1" colspan="1" align="center">3</td><td rowspan="1" colspan="1" align="center">39822076</td><td rowspan="1" colspan="1" align="center"><em>MYRIP</em></td><td rowspan="1" colspan="1" align="center">0.5%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">1.65 × 10<sup>−7</sup></td><td rowspan="1" colspan="1" align="center">4.07 (2.4-6.87)</td><td rowspan="1" colspan="1" align="center">74%</td><td rowspan="1" colspan="1" align="center">2 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">4.74 × 10<sup>−5</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs10170236</td><td rowspan="1" colspan="1" align="center">2</td><td rowspan="1" colspan="1" align="center">150165870</td><td rowspan="1" colspan="1" align="center"><em>LOC642340</em></td><td rowspan="1" colspan="1" align="center">25.6%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">3.92 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">1.45 (1.24-1.69)</td><td rowspan="1" colspan="1" align="center">66%</td><td rowspan="1" colspan="1" align="center">5.07 × 10<sup>−7</sup></td><td rowspan="1" colspan="1" align="center">.0035</td></tr><tr><td rowspan="1" colspan="1" align="left">rs6683977</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">66541688</td><td rowspan="1" colspan="1" align="center"><em>PDE4B</em></td><td rowspan="1" colspan="1" align="center">44.9%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">5.13 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">1.41 (1.22-1.64)</td><td rowspan="1" colspan="1" align="center">63%</td><td rowspan="1" colspan="1" align="center">5.9 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">.081</td></tr><tr><td rowspan="1" colspan="1" align="left">rs1402612</td><td rowspan="1" colspan="1" align="center">12</td><td rowspan="1" colspan="1" align="center">77517496</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">2.8%</td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">1.85 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">2.45 (1.63-3.69)</td><td rowspan="1" colspan="1" align="center">59%</td><td rowspan="1" colspan="1" align="center">.0059</td><td rowspan="1" colspan="1" align="center">1.1 × 10<sup>−4</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs7578361</td><td rowspan="1" colspan="1" align="center">2</td><td rowspan="1" colspan="1" align="center">150105464</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">27.6%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">8.40 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">1.4 (1.21-1.63)</td><td rowspan="1" colspan="1" align="center">59%</td><td rowspan="1" colspan="1" align="center">1.65 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">.0033</td></tr><tr><td rowspan="1" colspan="1" align="left">rs17837497</td><td rowspan="1" colspan="1" align="center">7</td><td rowspan="1" colspan="1" align="center">139349062</td><td rowspan="1" colspan="1" align="center"><em>TBXAS1</em></td><td rowspan="1" colspan="1" align="center">1.6%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">1.89 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">2.34 (1.65-3.31)</td><td rowspan="1" colspan="1" align="center">56%</td><td rowspan="1" colspan="1" align="center">6.63 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">7.8 × 10<sup>−4</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs1496766</td><td rowspan="1" colspan="1" align="center">7</td><td rowspan="1" colspan="1" align="center">78169401</td><td rowspan="1" colspan="1" align="center"><em>MAGI2</em></td><td rowspan="1" colspan="1" align="center">1.4%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">5.45 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">2.84 (1.81-4.44)</td><td rowspan="1" colspan="1" align="center">55%</td><td rowspan="1" colspan="1" align="center">2.41 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">6.45 × 10<sup>−6</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs9958208</td><td rowspan="1" colspan="1" align="center">18</td><td rowspan="1" colspan="1" align="center">38845082</td><td rowspan="1" colspan="1" align="center"><em>RIT2</em></td><td rowspan="1" colspan="1" align="center">9.9%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">5.12 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">1.62 (1.32-1.99)</td><td rowspan="1" colspan="1" align="center">55%</td><td rowspan="1" colspan="1" align="center">1.93 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">4.68 × 10<sup>−4</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs9578871</td><td rowspan="1" colspan="1" align="center">13</td><td rowspan="1" colspan="1" align="center">24977627</td><td rowspan="1" colspan="1" align="center"><em>ATP8A2</em></td><td rowspan="1" colspan="1" align="center">33.4%</td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">2.08 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.37 (1.18-1.58)</td><td rowspan="1" colspan="1" align="center">52%</td><td rowspan="1" colspan="1" align="center">7.10 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">.0016</td></tr><tr><td rowspan="1" colspan="1" align="left">rs41322152</td><td rowspan="1" colspan="1" align="center">10</td><td rowspan="1" colspan="1" align="center">71710811</td><td rowspan="1" colspan="1" align="center"><em>NPFFR1</em></td><td rowspan="1" colspan="1" align="center">1.2%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">8.33 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">2.52 (1.68-3.79)</td><td rowspan="1" colspan="1" align="center">52%</td><td rowspan="1" colspan="1" align="center">2.02 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">.0027</td></tr><tr><td rowspan="1" colspan="1" align="left">rs7320729</td><td rowspan="1" colspan="1" align="center">13</td><td rowspan="1" colspan="1" align="center">24962148</td><td rowspan="1" colspan="1" align="center"><em>ATP8A2</em></td><td rowspan="1" colspan="1" align="center">47.2%</td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">1.35 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.39 (1.2-1.61)</td><td rowspan="1" colspan="1" align="center">51%</td><td rowspan="1" colspan="1" align="center">2.69 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">7.77 × 10<sup>−5</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs546784</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">66535054</td><td rowspan="1" colspan="1" align="center"><em>PDE4B</em></td><td rowspan="1" colspan="1" align="center">45.7%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">9.22 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">1.4 (1.2-1.62)</td><td rowspan="1" colspan="1" align="center">51%</td><td rowspan="1" colspan="1" align="center">.0019</td><td rowspan="1" colspan="1" align="center">.087</td></tr><tr><td rowspan="1" colspan="1" align="left">rs7099696</td><td rowspan="1" colspan="1" align="center">10</td><td rowspan="1" colspan="1" align="center">102946382</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1.7%</td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">1.17 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">2.57 (1.68-3.92)</td><td rowspan="1" colspan="1" align="center">47%</td><td rowspan="1" colspan="1" align="center">1.32 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">9.37 × 10<sup>−5</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs12464261</td><td rowspan="1" colspan="1" align="center">2</td><td rowspan="1" colspan="1" align="center">69227954</td><td rowspan="1" colspan="1" align="center"><em>ANTXR1</em></td><td rowspan="1" colspan="1" align="center">46.5%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">2.79 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.37 (1.18-1.59)</td><td rowspan="1" colspan="1" align="center">47%</td><td rowspan="1" colspan="1" align="center">6.86 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">7.1 × 10<sup>−4</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs879286</td><td rowspan="1" colspan="1" align="center">14</td><td rowspan="1" colspan="1" align="center">32777047</td><td rowspan="1" colspan="1" align="center"><em>NPAS3</em></td><td rowspan="1" colspan="1" align="center">3.3%</td><td rowspan="1" colspan="1" align="center">G</td><td rowspan="1" colspan="1" align="center">2.34 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.95 (1.43-2.66)</td><td rowspan="1" colspan="1" align="center">46%</td><td rowspan="1" colspan="1" align="center">3.49 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">4.9 × 10<sup>−4</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs7320702</td><td rowspan="1" colspan="1" align="center">13</td><td rowspan="1" colspan="1" align="center">24975538</td><td rowspan="1" colspan="1" align="center"><em>ATP8A2</em></td><td rowspan="1" colspan="1" align="center">33.5%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">2.22 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.37 (1.19-1.59)</td><td rowspan="1" colspan="1" align="center">45%</td><td rowspan="1" colspan="1" align="center">4.20 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">0.0013</td></tr><tr><td rowspan="1" colspan="1" align="left">rs992435</td><td rowspan="1" colspan="1" align="center">7</td><td rowspan="1" colspan="1" align="center">96888739</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">2.5%</td><td rowspan="1" colspan="1" align="center">G</td><td rowspan="1" colspan="1" align="center">4.66 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">2.12 (1.48-3.04)</td><td rowspan="1" colspan="1" align="center">40%</td><td rowspan="1" colspan="1" align="center">3.38 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">4.47 × 10<sup>−6</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs6953777</td><td rowspan="1" colspan="1" align="center">7</td><td rowspan="1" colspan="1" align="center">10927258</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">1.2%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">4.91 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">2.62 (1.64-4.16)</td><td rowspan="1" colspan="1" align="center">39%</td><td rowspan="1" colspan="1" align="center">2.4 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">.0049</td></tr><tr><td rowspan="1" colspan="1" align="left">rs696518</td><td rowspan="1" colspan="1" align="center">3</td><td rowspan="1" colspan="1" align="center">137602990</td><td rowspan="1" colspan="1" align="center"><em>STAG1</em></td><td rowspan="1" colspan="1" align="center">40.9%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">4.71 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.36 (1.17-1.58)</td><td rowspan="1" colspan="1" align="center">39%</td><td rowspan="1" colspan="1" align="center">.0016</td><td rowspan="1" colspan="1" align="center">.015</td></tr><tr><td rowspan="1" colspan="1" align="left">rs4297844</td><td rowspan="1" colspan="1" align="center">2</td><td rowspan="1" colspan="1" align="center">150108354</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">25.3%</td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">7.60 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.36 (1.17-1.58)</td><td rowspan="1" colspan="1" align="center">38%</td><td rowspan="1" colspan="1" align="center">1.64 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">.028</td></tr><tr><td rowspan="1" colspan="1" align="left">rs10153318</td><td rowspan="1" colspan="1" align="center">17</td><td rowspan="1" colspan="1" align="center">13265827</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">24.8%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">2.10 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.41 (1.21-1.66)</td><td rowspan="1" colspan="1" align="center">38%</td><td rowspan="1" colspan="1" align="center">6.29 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">.00965</td></tr><tr><td rowspan="1" colspan="1" align="left">rs6538901</td><td rowspan="1" colspan="1" align="center">12</td><td rowspan="1" colspan="1" align="center">98043535</td><td rowspan="1" colspan="1" align="center"><em>ANKS1B</em></td><td rowspan="1" colspan="1" align="center">36.5%</td><td rowspan="1" colspan="1" align="center">G</td><td rowspan="1" colspan="1" align="center">6.56 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.38 (1.18-1.62)</td><td rowspan="1" colspan="1" align="center">37%</td><td rowspan="1" colspan="1" align="center">.0049</td><td rowspan="1" colspan="1" align="center">.011</td></tr><tr><td rowspan="1" colspan="1" align="left">rs12018180</td><td rowspan="1" colspan="1" align="center">13</td><td rowspan="1" colspan="1" align="center">25035957</td><td rowspan="1" colspan="1" align="center"><em>ATP8A2</em></td><td rowspan="1" colspan="1" align="center">33.2%</td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">7.38 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.34 (1.16-1.55)</td><td rowspan="1" colspan="1" align="center">37%</td><td rowspan="1" colspan="1" align="center">1.7 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">3.2 × 10<sup>−4</sup></td></tr><tr><td rowspan="1" colspan="1" align="left">rs9624873</td><td rowspan="1" colspan="1" align="center">22</td><td rowspan="1" colspan="1" align="center">24260784</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">4.4%</td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">5.50 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">1.8 (1.35-2.39)</td><td rowspan="1" colspan="1" align="center">37%</td><td rowspan="1" colspan="1" align="center">.0058</td><td rowspan="1" colspan="1" align="center">.14</td></tr></tbody></table></div><div id="largeobj_idm140719301324576" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3501717/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="idm140719315581680"><p id="__p24" class="p p-first">Chromosomal location is based on hg19. Validation frequency represents the number of times a SNP was successfully replicated out of 100 rounds of resampling (see “GWAS for germline SNP genotypes related to risk of relapse”). <em>P</em> values indicate the statistical significance of the associations between SNP genotypes and ALL relapse as determined by Fine and Gray hazard ratio regression model. Hazard ratio (HR) represents the increase in relapse risk for each copy of the risk allele compared with patients who do not carry the risk allele. Independent prognostic value is examined by multivariate analyses adjusting for known relapse risk factors (ie, ancestry, molecular subtypes/lineage, age, leukocyte count at diagnosis, ploidy, and MRD) and by association within patients with negative for MRD at the end of remission induction therapy.</p><p id="__p25" class="p p-last">chr indicates chromosome; and CI, confidence interval.</p></div></div></div><p id="__p26">Across the genome, the strongest association with relapse risk was observed at 14q22.1 in the <em>PYGL</em> gene (rs7142143). Each copy of the C allele at this <em>PYGL</em> intronic SNP (rs7142143) rendered a 3.6-fold increase in the risk of relapse (<em>P</em> = 6.7 × 10<sup>−9</sup>, <a href="/pmc/articles/PMC3501717/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>) and an association of this SNP with relapse was replicated in 79 of 100 rounds of resampling (<a href="/pmc/articles/PMC3501717/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC3501717/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719325004592" class="figure"><a href="/pmc/articles/PMC3501717/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3501717_zh89991299130002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zh89991299130002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3501717/bin/zh89991299130002.jpg"></a></div><div id="largeobj_idm140719325004592" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3501717/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC3501717/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p27"><strong>Association of genotypes at the <em>PYGL</em> SNP (rs7142143) with the risk of ALL relapse.</strong> The cumulative incidence of any relapse was compared for each genotype group at rs7142143 (CC/CT or TT) in all patients (A) and in those patients negative for MRD at the end of remission induction (B). The <em>P</em> value was estimated using the Fine and Gray hazard regression model.</p></div></div></div><p id="__p28" class="p p-last">Many GWAS investigations of treatment response neglect to consider the confounding of germline SNP genotypes with known prognostic factors. In the present study, of 134 relapse SNPs, 73 were associated with one or more clinical presenting features that are recognized as prognostic in childhood ALL (<em>P</em> &lt; .05, supplemental Table 2). For example, 32 SNPs had alleles that were related to leukocyte count ≥ 50 000/μL at diagnosis and to relapse risk; genotypes at 19 SNPs were enriched in children older than 10 years and associated with relapse; 16 SNPs were associated with hyperdiploid ALL (DNA index ≥ 1.16) and with a lower risk of relapse. In addition, 61 of 134 SNPs were associated with ALL molecular subtype and/or lineage (<em>MLL</em> rearrangements; <em>ETV6-RUNX1</em>, <em>TCF3-PBX1</em>, or <em>BCR-ABL1</em>; or T-cell ALL). However, 133 of 134 relapse SNPs remained prognostic after adjusting for all known risk factors (presenting features and MRD, supple-mental <a href="/pmc/articles/PMC3501717/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>), indicating their independent associations with relapse risk.</p></div><div id="__sec13" class="sec"><h3 id="__sec13title">Associations of relapse SNPs with MRD</h3><p id="__p29" class="p p-first-last">Early reduction of leukemia burden, as determined by MRD status at the end of remission induction therapy, is highly prognostic for ALL relapse. However, the majority of relapses still occur among patients with negative MRD status.<sup><a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115569">14</a></sup> Therefore, in the present study, we characterized the relationships between the 134 relapse SNPs with this early treatment response measure and determined the prognostic value of germline polymorphisms. Of 134 relapse SNPs, 133 (99%) remained prognostic after adjusting for MRD (<em>P</em> &lt; .05) and 110 (82%) were significantly associated with relapse even within MRD<sup>−</sup> patients (eg, rs7142143, which is shown in <a href="/pmc/articles/PMC3501717/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>B with full listing in supplemental Table 1), strongly suggesting that these genetic variants substantially contribute to interpatient variability in outcome beyond what is explained by MRD. Of 134 relapse SNPs, 34 were significantly associated with MRD, with the alleles related to higher MRD status always linked to higher relapse risk. For example, genotypes at rs10834571 in the <em>LUZP2</em> gene were most strongly associated with MRD (<em>P</em> = 3 × 10<sup>−4</sup>). Although the G allele at this SNP was related to higher MRD at the end of remission induction and a subsequent higher risk of relapse, it also identified patients at risk of relapse even within the MRD<sup>−</sup> patient population (supplemental Figure 2).</p></div><div id="__sec14" class="sec sec-last"><h3 id="__sec14title">Relationships between relapse SNPs and pharmacologic phenotypes</h3><p id="__p30" class="p p-first">To explore the mechanisms by which SNPs might influence treatment outcome of ALL, we examined the association of the 134 relapse SNPs with 4 pharmacokinetic and pharmacodynamic endophenotypes available in a subset of patients: methotrexate plasma clearance, intracellular accumulation of polyglutamated (active) methotrexate, dexamethasone plasma clearance, and asparaginase antibody levels. Three relapse SNPs were associated with methotrexate plasma clearance after high-dose intravenous methotrexate, and all 3 genotypes were related to low clearance (more drug exposure) and lower risk of relapse. Genotypes at 7 SNPs were associated with polyglutamated methotrexate levels in ALL blasts, 5 of which were associated with reduced levels of methotrexate polyglutamate and a higher relapse risk, including 3 SNPs within the <em>PDE4B</em> gene. Dexamethasone plasma clearance differed significantly by genotype at 4 relapse SNPs, 2 of which were within the ABC transporter gene <em>ABCB1</em> and both associated with higher dexamethasone clearance and a higher relapse risk (<a href="/pmc/articles/PMC3501717/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a>). Finally, 5 relapse SNPs were related to higher asparaginase Ab levels, 2 of which were associated with a higher relapse rate. As summarized in <a href="/pmc/articles/PMC3501717/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>, 14 of 134 relapse SNPs were significant for at least 1 of the 4 pharmacologic phenotypes in a manner consistent with a pharmacokinetically intuitive association with relapse (ie, lower drug exposure translated into a higher risk of relapse).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC3501717/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719297384912" class="figure"><a href="/pmc/articles/PMC3501717/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3501717_zh89991299130003.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is zh89991299130003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3501717/bin/zh89991299130003.jpg"></a></div><div id="largeobj_idm140719297384912" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3501717/figure/F3/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC3501717/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p31"><strong>An example of relapse-associated SNPs affecting pharmacokinetics and pharmacodynamics of antileukemic agents.</strong> Genotype at <em>ABCB1</em> SNP rs10264856 is associated with both ALL relapse (A) and dexamethasone apparent oral plasma clearance (B). Note that the C allele is linked to lower dexamethasone clearance and also lower cumulative incidence of relapse. The association of SNP genotype with clearance and with relapse was estimated by linear regression and the Fine and Gray hazard regression model, respectively. Dexamethasone clearance was determined in St Jude Total XV protocol at week 7 of continuation therapy, which is shown for those in the standard-/high-risk arm.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p32">Relationships between relapse-associated SNPs and pharmacokinetics and pharmacodynamics of antileukemic drugs</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719317181600" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th colspan="5" rowspan="1" align="left">SNP information<hr></th><th colspan="2" rowspan="1" align="center">Association with ALL relapse<hr></th><th colspan="2" rowspan="1" align="center">Association with asparaginase antibody<hr></th></tr><tr><th rowspan="1" colspan="1" align="center">SNP ID</th><th rowspan="1" colspan="1" align="center">Chr</th><th rowspan="1" colspan="1" align="center">Position</th><th rowspan="1" colspan="1" align="center">Gene</th><th rowspan="1" colspan="1" align="center">MAF</th><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center">Risk allele</th><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center">The allele with higher antibody</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left">rs251177</td><td rowspan="1" colspan="1" align="center">5</td><td rowspan="1" colspan="1" align="center">141007068</td><td rowspan="1" colspan="1" align="center"><em>FCHSD1</em></td><td rowspan="1" colspan="1" align="center">0.22</td><td rowspan="1" colspan="1" align="center">6.53 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">.0053</td><td rowspan="1" colspan="1" align="center">C</td></tr><tr><td rowspan="1" colspan="1" align="left">rs6773449</td><td rowspan="1" colspan="1" align="center">3</td><td rowspan="1" colspan="1" align="center">26322367</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.03</td><td rowspan="1" colspan="1" align="center">2.15 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">.043</td><td rowspan="1" colspan="1" align="center">C</td></tr></tbody></table></div><div id="largeobj_idm140719317181600" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3501717/table/T3/?report=objectonly">Open in a separate window</a></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719327194448" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th rowspan="2" colspan="7"></th><th colspan="2" rowspan="1" align="center">Association with dexamethasone clearance<hr></th></tr><tr><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center">The allele with higher clearance</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left">rs6007758</td><td rowspan="1" colspan="1" align="center">22</td><td rowspan="1" colspan="1" align="center">46668860</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.01</td><td rowspan="1" colspan="1" align="center">3.74 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">.038</td><td rowspan="1" colspan="1" align="center">A</td></tr><tr><td rowspan="1" colspan="1" align="left">rs41488548</td><td rowspan="1" colspan="1" align="center">11</td><td rowspan="1" colspan="1" align="center">32432060</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.07</td><td rowspan="1" colspan="1" align="center">6.03 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">.0052</td><td rowspan="1" colspan="1" align="center">A</td></tr><tr><td rowspan="1" colspan="1" align="left">rs10264856</td><td rowspan="1" colspan="1" align="center">7</td><td rowspan="1" colspan="1" align="center">87100517</td><td rowspan="1" colspan="1" align="center"><em>ABCB1; RUNDC3B</em></td><td rowspan="1" colspan="1" align="center">0.11</td><td rowspan="1" colspan="1" align="center">1.84 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">.029</td><td rowspan="1" colspan="1" align="center">T</td></tr><tr><td rowspan="1" colspan="1" align="left">rs4728709</td><td rowspan="1" colspan="1" align="center">7</td><td rowspan="1" colspan="1" align="center">87071538</td><td rowspan="1" colspan="1" align="center"><em>ABCB1</em></td><td rowspan="1" colspan="1" align="center">0.11</td><td rowspan="1" colspan="1" align="center">3.06 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">.0083</td><td rowspan="1" colspan="1" align="center">A</td></tr></tbody></table></div><div id="largeobj_idm140719327194448" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3501717/table/T3/?report=objectonly">Open in a separate window</a></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719325305424" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th rowspan="2" colspan="7"></th><th colspan="2" rowspan="1" align="center">Association with MTXPG accumulation<hr></th></tr><tr><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center">The allele with lower MTXPG</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left">rs6683977</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">66541688</td><td rowspan="1" colspan="1" align="center"><em>PDE4B</em></td><td rowspan="1" colspan="1" align="center">0.45</td><td rowspan="1" colspan="1" align="center">5.13 × 10<sup>−6</sup></td><td rowspan="1" colspan="1" align="center">C</td><td rowspan="1" colspan="1" align="center">.042</td><td rowspan="1" colspan="1" align="center">C</td></tr><tr><td rowspan="1" colspan="1" align="left">rs524770</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">66538810</td><td rowspan="1" colspan="1" align="center"><em>PDE4B</em></td><td rowspan="1" colspan="1" align="center">0.42</td><td rowspan="1" colspan="1" align="center">9.12 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">.0042</td><td rowspan="1" colspan="1" align="center">A</td></tr><tr><td rowspan="1" colspan="1" align="left">rs641262</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">66545937</td><td rowspan="1" colspan="1" align="center"><em>PDE4B</em></td><td rowspan="1" colspan="1" align="center">0.45</td><td rowspan="1" colspan="1" align="center">9.47 × 10<sup>−5</sup></td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">.017</td><td rowspan="1" colspan="1" align="center">A</td></tr><tr><td rowspan="1" colspan="1" align="left">rs4265132</td><td rowspan="1" colspan="1" align="center">7</td><td rowspan="1" colspan="1" align="center">118907598</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.04</td><td rowspan="1" colspan="1" align="center">2.01 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">.047</td><td rowspan="1" colspan="1" align="center">T</td></tr><tr><td rowspan="1" colspan="1" align="left">rs16965335</td><td rowspan="1" colspan="1" align="center">15</td><td rowspan="1" colspan="1" align="center">51023401</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.03</td><td rowspan="1" colspan="1" align="center">2.31 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">T</td><td rowspan="1" colspan="1" align="center">.013</td><td rowspan="1" colspan="1" align="center">T</td></tr></tbody></table></div><div id="largeobj_idm140719325305424" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3501717/table/T3/?report=objectonly">Open in a separate window</a></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140719327232544" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead valign="bottom"><tr><th rowspan="2" colspan="7"></th><th colspan="2" rowspan="1" align="center">Association with MTX clearance<hr></th></tr><tr><th rowspan="1" colspan="1" align="center"><em>P</em></th><th rowspan="1" colspan="1" align="center">The allele with higher clearance</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left">rs7141601</td><td rowspan="1" colspan="1" align="center">14</td><td rowspan="1" colspan="1" align="center">83865815</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.13</td><td rowspan="1" colspan="1" align="center">1.44 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">.017</td><td rowspan="1" colspan="1" align="center">A</td></tr><tr><td rowspan="1" colspan="1" align="left">rs2613079</td><td rowspan="1" colspan="1" align="center">4</td><td rowspan="1" colspan="1" align="center">181846695</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.01</td><td rowspan="1" colspan="1" align="center">2.02 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">A</td><td rowspan="1" colspan="1" align="center">.023</td><td rowspan="1" colspan="1" align="center">A</td></tr><tr><td rowspan="1" colspan="1" align="left">rs12751530</td><td rowspan="1" colspan="1" align="center">1</td><td rowspan="1" colspan="1" align="center">41129367</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1" align="center">0.17</td><td rowspan="1" colspan="1" align="center">2.45 × 10<sup>−4</sup></td><td rowspan="1" colspan="1" align="center">G</td><td rowspan="1" colspan="1" align="center">.034</td><td rowspan="1" colspan="1" align="center">G</td></tr></tbody></table></div><div id="largeobj_idm140719327232544" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3501717/table/T3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="idm140719317687120"><p id="__p33" class="p p-first">Chromosomal position is based on hg19. <em>P</em> values indicate the statistical significance of the associations of SNP genotypes with ALL relapse (determined by Fine and Gray hazard regression model) and with pharmacokinetic and pharmacodynamic phenotypes (determined by linear regression).</p><p id="__p34" class="p p-last">chr indicates chromosome; MAF, minor allele frequency; MTX, methotrexate; and MTXPG, methotrexate polyglutamate.</p></div></div></div></div></div><div id="__sec15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec15title">Discussion</h2><p id="__p35" class="p p-first">Although current risk classification schemes identify children with more aggressive ALL, a substantial portion of these high-risk patients still do not respond to more intensive chemotherapy. Conversely, a substantial portion of the children with ALL who eventually relapse are initially classified as being low risk at diagnosis.<sup><a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115573">24</a></sup> For example, even for MRD (the best clinical predictor of relapse in childhood ALL), more than 50% of relapse cases exhibit undetectable levels of leukemia burden after initial therapy and therefore cannot be reclassified for more intense treatment.<sup><a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115582">3</a>,<a href="#B4" rid="B4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115540">4</a>,<a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115588">14</a></sup> For these reasons, it was particularly impressive that in the present study, germline variations distinguished patients at risk of relapse even within the group showing negative MRD, indicating that these genetic factors can significantly improve current models of risk stratification.</p><p id="__p36">Capitalizing on the nearly population-based capture of childhood ALL patients in the United States to clinical trials led by the COG and St Jude, our present study systematically identified germline genetic variations associated with risk of relapse among 2535 children with ALL, the largest group of children with cancer ever studied for genetic determinants of outcome. Nevertheless, the number of patients receiving identical therapy is too small to separate patients into simple “discovery versus replication” cohorts for traditional genome-wide outcome analyses. Because therapy so strongly affects the likelihood of relapse, each discovery and replication cohort must be balanced for therapy arms. Therefore, we developed an iterative resampling approach<sup><a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115545">25</a>,<a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115548">26</a></sup> in which patients were divided into a discovery and a replication cohort 100 times, each time balancing on treatment arm, ancestry, CNS status, and treatment outcome. By conducting the study in this manner, the replicated SNPs would be expected to be robust for multiple types of therapy. In fact, 133 of 134 relapse SNPs selected using this approach maintained prognostic significance after adjusting for treatment regimens and patient characteristics.</p><p id="__p37">The top-ranked SNP is in the <em>PYGL</em> gene. <em>PYGL</em>, glycogen phosphorylase, is a target of adenosine monophosphate (<a href="http://www.drugbank.ca/drugs/DB00131" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.drugbank.ca/drugs/DB00131</a>), which plays a critical role in response to antileukemic agents such as mercaptopurine and methotrexate.<sup><a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115585">27</a></sup> Interestingly, <em>PYGL</em> expression in diagnostic ALL blasts was shown to be positively correlated with in vitro response to prednisolone in 173 children with ALL (<em>P</em> = .002).<sup><a href="#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115572">28</a></sup>
<em>PYGL</em> has also been shown to be significantly overexpressed in a multidrug-resistant cancer cell line.<sup><a href="#B29" rid="B29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115551">29</a></sup> Another interesting hit among the top-ranking genes is <em>PDE4B</em>, which encodes phosphodiesterase 4B, the primary regulator of cyclic AMP signaling in B lymphocytes.<sup><a href="#B30" rid="B30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115568">30</a>,<a href="#B31" rid="B31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115560">31</a></sup> Prior studies have already shown that inhibition of PDE4B induces apoptosis in chronic lymphoblastic leukemia and diffuse large cell lymphoma<sup><a href="#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115587">32</a>,<a href="#B33" rid="B33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115578">33</a></sup> and sensitizes cells to glucocorticoid-induced cell death.<sup><a href="#B34" rid="B34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_523659469">34</a>,<a href="#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115591">35</a></sup> In ALL, pharmacologic inhibition of the PDE4 results in growth suppression and dexamethasone sensitivity,<sup><a href="#B36" rid="B36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115555">36</a></sup> suggesting glucocorticoid response as a plausible mechanism by which PDE4B is linked to ALL relapse.</p><p id="__p38">Over the past 50 years of studying prognostic features for ALL, many have been associated with relapse (eg, high leukocyte count, age ≥ 10 years, and blasts that are not hyperdiploid or carry unfavorable translations such as <em>MLL</em> rearrangements or <em>BCR-ABL1</em>); however, the mechanisms by which these features confer a higher relapse risk after chemotherapy remains mostly unclear.<sup><a href="#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115574">1</a></sup> In the present study, we did find that a majority (73 of 134) of relapse SNPs were related to one or more clinical presenting features. Although nearly all SNPs remained prognostic after adjusting for those features, there may nevertheless be mechanisms by which germline polymorphisms associate with both poor outcome and with presenting ALL features.</p><p id="__p39">We found herein that 14 of the 134 relapse SNPs (11%) were also associated with unfavorable pharmacokinetics of commonly used antileukemic agents, suggesting that some inherited variation is likely to affect relapse by affecting host disposition of antileukemic agents. Two SNPs annotated to <em>ABCB1</em>, rs10264856 and rs4728709, are in linkage disequilibrium with each other (<em>r</em><sup>2</sup> &gt; 0.9) and were associated with increased dexamethasone apparent oral clearance. This would translate into lower plasma levels of dexamethasone, a phenotype that we have shown previously to be related to higher risk of ALL relapse.<sup><a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115590">23</a></sup> Interestingly, many drugs that are used to treat ALL, including glucocorticoids such as dexamethasone,<sup><a href="#B37" rid="B37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115539">37</a></sup> anthracyclines,<sup><a href="#B38" rid="B38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115543">38</a></sup> and vincristine,<sup><a href="#B38" rid="B38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115553">38</a></sup> are substrates for the ABCB1 transporter (also known as MDR1 or multidrug resistance protein), and thus this association may be plausibly linked to both mechanisms of intrinsic blast resistance and to unfavorable host pharmacokinetic characteristics. Candidate SNPs in <em>ABCB1</em> have been shown previously to be associated with outcome in ALL.<sup><a href="#B39" rid="B39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115547">39</a>,<a href="#B40" rid="B40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_286115544">40</a></sup></p><p id="__p40" class="p p-last">We conclude that germline SNPs were associated with risk of ALL relapse in this large cohort of newly diagnosed children with ALL, even among patients who were negative for MRD, so inherited SNP genotypes may be a useful additional feature for risk classification in this disease.</p></div><div id="__sec16" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec16title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="PMC_1">

<!--caption a9--><strong>Supplemental Tables and Figures:</strong>

<div class="sup-box half_rhythm" id="idm140719312071248"><a href="/pmc/articles/PMC3501717/bin/supp_120_20_4197__index.html" data-ga-action="click_feat_suppl">Click here to view.</a></div>

</div></div><div id="idm140719392304960" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140719392304960title">Acknowledgments</h2><div class="sec"><p id="__p43">The authors thank all patients and their parents who participated in the St Jude Total Therapy XIIIB/XV and COG P9906/P9904/P9905 studies; clinicians and research staff at the St Jude and COG institutions; Dr Jeannette Pullen from the University of Mississippi at Jackson and Dr Andrew Carroll from the University of Alabama at Birmingham for assistance in classification of patients with ALL; and Dr Mark Shriver at the Pennsylvania State University for sharing SNP genotype data of the 105 Native-American references.</p><p id="__p44">This work was supported by the National Institutes of Health (grants CA142665, CA21765, CA158568, CA156449, CA36401, CA98543, CA114766, CA140729, and U01GM92666) and the American Lebanese Syrian Associated Charities (ALSAC). The Jeffrey Pride Foundation and the National Childhood Cancer Foundation provided support for genome-wide genotyping of the COG specimens. S.P.H. holds the Ergen Family Chair in Pediatric Cancer. J.J.Y. is supported by an American Society of Hematology Scholar Award and an Alex's Lemonade Stand Foundation for Childhood Cancer Young Investigator Grant. These sponsors provided financial support for the St Jude and the COG clinical trials, as well as for the genetic studies, but were not directly involved in the design or execution of the study, genomic data collection/management/analysis, or review/approval of this manuscript.</p></div></div><div id="idm140719318484624" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140719318484624title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm140719318484496"></p><p id="__p41" class="p p-first-last">The online version of this article contains a data supplement.</p><p></p><p class="fn sec" id="idm140719318483632"></p><p id="__p42" class="p p-first-last">The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.</p><p></p></div></div><div id="__sec17" class="tsec bk-sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec17title">Authorship</h2><!--/article/back/sec/--><p id="__p45" class="p p-first">Contribution: J.J.Y., C.C., and M.V.R. conceived and designed the study; M.D., D.C., Y.F., G.N., M.J.B., N.J.W., P.L.M., W.P.B., B.C., C.L.W., S.P.H., W.E.E., C.-H.P., M.L., and M.V.R. acquired the data; J.J.Y. and M.V.R. wrote the manuscript; J.J.Y., D.C., G.N., C.L.W., S.P.H., W.E.E., C.-H.P., and M.V.R. critically revised the manuscript for important intellectual content; C.C., M.D., X.C., W.Y., N.C., and P.S. performed the statistical analysis; and D.C., M.J.B., G.H.R., W.L.C., S.P.H., W.E.E., and M.V.R. obtained funding for the study.</p><p id="__p46">Conflict-of-interest disclosure: The authors declare no competing financial interests.</p><p id="__p47" class="p p-last">Correspondence: Mary V. Relling, St Jude Children's Research Hospital, Department of Pharmaceutical Sciences, 262 Danny Thomas Pl, Memphis, TN 38105; e-mail: <a href="mailto:dev@null" data-email="gro.edujts@gniller.yram" class="oemail">gro.edujts@gniller.yram</a>.</p></div><div id="idm140719392302496" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140719392302496title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="element-citation">Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">354</span>(2):166–178.</span> [<a href="/pubmed/16407512" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Treatment+of+acute+lymphoblastic+leukemia.&amp;author=CH+Pui&amp;author=WE+Evans&amp;volume=354&amp;issue=2&amp;publication_year=2006&amp;pages=166-178&amp;pmid=16407512&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="element-citation">Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Semin Hematol. </span>2009;<span class="ref-vol">46</span>(1):52–63.</span> [<a href="/pubmed/19100368" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Hematol&amp;title=Treatment+of+childhood+acute+lymphoblastic+leukemia.&amp;author=M+Stanulla&amp;author=M+Schrappe&amp;volume=46&amp;issue=1&amp;publication_year=2009&amp;pages=52-63&amp;pmid=19100368&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="element-citation">Schrappe M, Reiter A, Ludwig WD, et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. <span><span class="ref-journal">Blood. </span>2000;<span class="ref-vol">95</span>(11):3310–3322.</span> [<a href="/pubmed/10828010" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Improved+outcome+in+childhood+acute+lymphoblastic+leukemia+despite+reduced+use+of+anthracyclines+and+cranial+radiotherapy:+results+of+trial+ALL-BFM+90.+German-Austrian-Swiss+ALL-BFM+Study+Group.&amp;author=M+Schrappe&amp;author=A+Reiter&amp;author=WD+Ludwig&amp;volume=95&amp;issue=11&amp;publication_year=2000&amp;pages=3310-3322&amp;pmid=10828010&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="element-citation">Schrappe M, Reiter A, Zimmermann M, et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. <span><span class="ref-journal">Leukemia. </span>2000;<span class="ref-vol">14</span>(12):2205–2222.</span> [<a href="/pubmed/11187912" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Long-term+results+of+four+consecutive+trials+in+childhood+ALL+performed+by+the+ALL-BFM+study+group+from+1981+to+1995.+Berlin-Frankfurt-Munster.&amp;author=M+Schrappe&amp;author=A+Reiter&amp;author=M+Zimmermann&amp;volume=14&amp;issue=12&amp;publication_year=2000&amp;pages=2205-2222&amp;pmid=11187912&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="element-citation">Dördelmann M, Reiter A, Borkhardt A, et al.  Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. <span><span class="ref-journal">Blood. </span>1999;<span class="ref-vol">94</span>(4):1209–1217.</span> [<a href="/pubmed/10438708" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Prednisone+response+is+the+strongest+predictor+of+treatment+outcome+in+infant+acute+lymphoblastic+leukemia.&amp;author=M+Dördelmann&amp;author=A+Reiter&amp;author=A+Borkhardt&amp;volume=94&amp;issue=4&amp;publication_year=1999&amp;pages=1209-1217&amp;pmid=10438708&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="element-citation">Campana D. Minimal residual disease in acute lymphoblastic leukemia. <span><span class="ref-journal">Semin Hematol. </span>2009;<span class="ref-vol">46</span>(1):100–106.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2632881/">PMC free article</a>]</span> [<a href="/pubmed/19100372" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Hematol&amp;title=Minimal+residual+disease+in+acute+lymphoblastic+leukemia.&amp;author=D+Campana&amp;volume=46&amp;issue=1&amp;publication_year=2009&amp;pages=100-106&amp;pmid=19100372&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="element-citation">Yang JJ, Cheng C, Yang W, et al.  Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. <span><span class="ref-journal">JAMA. </span>2009;<span class="ref-vol">301</span>(4):393–403.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2664534/">PMC free article</a>]</span> [<a href="/pubmed/19176441" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Genome-wide+interrogation+of+germline+genetic+variation+associated+with+treatment+response+in+childhood+acute+lymphoblastic+leukemia.&amp;author=JJ+Yang&amp;author=C+Cheng&amp;author=W+Yang&amp;volume=301&amp;issue=4&amp;publication_year=2009&amp;pages=393-403&amp;pmid=19176441&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="element-citation">Ansari M, Sauty G, Labuda M, et al.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">114</span>(7):1383–1386.</span> [<a href="/pubmed/19515727" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Polymorphisms+in+multidrug+resistance-associated+protein+gene+4+is+associated+with+outcome+in+childhood+acute+lymphoblastic+leukemia.&amp;author=M+Ansari&amp;author=G+Sauty&amp;author=M+Labuda&amp;volume=114&amp;issue=7&amp;publication_year=2009&amp;pages=1383-1386&amp;pmid=19515727&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="element-citation">Rocha JC, Cheng C, Liu W, et al.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>(12):4752–4758.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1895006/">PMC free article</a>]</span> [<a href="/pubmed/15713801" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Pharmacogenetics+of+outcome+in+children+with+acute+lymphoblastic+leukemia.&amp;author=JC+Rocha&amp;author=C+Cheng&amp;author=W+Liu&amp;volume=105&amp;issue=12&amp;publication_year=2005&amp;pages=4752-4758&amp;pmid=15713801&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="element-citation">Davies SM, Borowitz MJ, Rosner GL, et al.  Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. <span><span class="ref-journal">Blood. </span>2008;<span class="ref-vol">111</span>(6):2984–2990.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2265447/">PMC free article</a>]</span> [<a href="/pubmed/18182569" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Pharmacogenetics+of+minimal+residual+disease+response+in+children+with+B-precursor+acute+lymphoblastic+leukemia:+a+report+from+the+Children's+Oncology+Group.&amp;author=SM+Davies&amp;author=MJ+Borowitz&amp;author=GL+Rosner&amp;volume=111&amp;issue=6&amp;publication_year=2008&amp;pages=2984-2990&amp;pmid=18182569&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="element-citation">Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. <span><span class="ref-journal">J Clin Invest. </span>2007;<span class="ref-vol">117</span>(4):1049–1057.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1821067/">PMC free article</a>]</span> [<a href="/pubmed/17380207" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Mesenchymal+cells+regulate+the+response+of+acute+lymphoblastic+leukemia+cells+to+asparaginase.&amp;author=S+Iwamoto&amp;author=K+Mihara&amp;author=JR+Downing&amp;author=CH+Pui&amp;author=D+Campana&amp;volume=117&amp;issue=4&amp;publication_year=2007&amp;pages=1049-1057&amp;pmid=17380207&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="element-citation">Pui CH, Sandlund JT, Pei D, et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">104</span>(9):2690–2696.</span> [<a href="/pubmed/15251979" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Improved+outcome+for+children+with+acute+lymphoblastic+leukemia:+results+of+Total+Therapy+Study+XIIIB+at+St+Jude+Children's+Research+Hospital.&amp;author=CH+Pui&amp;author=JT+Sandlund&amp;author=D+Pei&amp;volume=104&amp;issue=9&amp;publication_year=2004&amp;pages=2690-2696&amp;pmid=15251979&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="element-citation">Pui CH, Campana D, Pei D, et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">360</span>(26):2730–2741.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2754320/">PMC free article</a>]</span> [<a href="/pubmed/19553647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Treating+childhood+acute+lymphoblastic+leukemia+without+cranial+irradiation.&amp;author=CH+Pui&amp;author=D+Campana&amp;author=D+Pei&amp;volume=360&amp;issue=26&amp;publication_year=2009&amp;pages=2730-2741&amp;pmid=19553647&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="element-citation">Borowitz MJ, Devidas M, Hunger SP, et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. <span><span class="ref-journal">Blood. </span>2008;<span class="ref-vol">111</span>(12):5477–5485.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2424148/">PMC free article</a>]</span> [<a href="/pubmed/18388178" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Clinical+significance+of+minimal+residual+disease+in+childhood+acute+lymphoblastic+leukemia+and+its+relationship+to+other+prognostic+factors:+a+Children's+Oncology+Group+study.&amp;author=MJ+Borowitz&amp;author=M+Devidas&amp;author=SP+Hunger&amp;volume=111&amp;issue=12&amp;publication_year=2008&amp;pages=5477-5485&amp;pmid=18388178&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="element-citation">Rabbee N, Speed TP. A genotype calling algorithm for affymetrix SNP arrays. <span><span class="ref-journal">Bioinformatics. </span>2006;<span class="ref-vol">22</span>(1):7–12.</span> [<a href="/pubmed/16267090" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=A+genotype+calling+algorithm+for+affymetrix+SNP+arrays.&amp;author=N+Rabbee&amp;author=TP+Speed&amp;volume=22&amp;issue=1&amp;publication_year=2006&amp;pages=7-12&amp;pmid=16267090&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="element-citation">Korn JM, Kuruvilla FG, McCarroll SA, et al.  Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. <span><span class="ref-journal">Nat Genet. </span>2008;<span class="ref-vol">40</span>(10):1253–1260.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2756534/">PMC free article</a>]</span> [<a href="/pubmed/18776909" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Genet&amp;title=Integrated+genotype+calling+and+association+analysis+of+SNPs,+common+copy+number+polymorphisms+and+rare+CNVs.&amp;author=JM+Korn&amp;author=FG+Kuruvilla&amp;author=SA+McCarroll&amp;volume=40&amp;issue=10&amp;publication_year=2008&amp;pages=1253-1260&amp;pmid=18776909&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="element-citation">Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. <span><span class="ref-journal">Genetics. </span>2000;<span class="ref-vol">155</span>(2):945–959.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1461096/">PMC free article</a>]</span> [<a href="/pubmed/10835412" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genetics&amp;title=Inference+of+population+structure+using+multilocus+genotype+data.&amp;author=JK+Pritchard&amp;author=M+Stephens&amp;author=P+Donnelly&amp;volume=155&amp;issue=2&amp;publication_year=2000&amp;pages=945-959&amp;pmid=10835412&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="element-citation">Mao X, Bigham AW, Mei R, et al.  A genomewide admixture mapping panel for Hispanic/Latino populations. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">80</span>(6):1171–1178.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1867104/">PMC free article</a>]</span> [<a href="/pubmed/17503334" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=A+genomewide+admixture+mapping+panel+for+Hispanic/Latino+populations.&amp;author=X+Mao&amp;author=AW+Bigham&amp;author=R+Mei&amp;volume=80&amp;issue=6&amp;publication_year=2007&amp;pages=1171-1178&amp;pmid=17503334&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="element-citation">Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. <span><span class="ref-journal">J Am Stat Assoc. </span>1999;<span class="ref-vol">94</span>(446):496–509.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Stat+Assoc&amp;title=A+proportional+hazards+model+for+the+subdistribution+of+a+competing+risk.&amp;author=JP+Fine&amp;author=RJ+Gray&amp;volume=94&amp;issue=446&amp;publication_year=1999&amp;pages=496-509&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="element-citation">Cheng C, Pounds SB, Boyett JM, Pei D, Kuo ML, Roussel MF. Statistical significance threshold criteria for analysis of microarray gene expression data. <span><span class="ref-journal">Stat Appl Genet Mol Biol. </span>2004;<span class="ref-vol">3</span></span> Article36. [<a href="/pubmed/16646816" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Stat+Appl+Genet+Mol+Biol&amp;title=Statistical+significance+threshold+criteria+for+analysis+of+microarray+gene+expression+data.&amp;author=C+Cheng&amp;author=SB+Pounds&amp;author=JM+Boyett&amp;author=D+Pei&amp;author=ML+Kuo&amp;volume=3&amp;publication_year=2004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="element-citation">Ramsey LB, Bruun GH, Yang W, et al.  Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. <span><span class="ref-journal">Genome Res. </span>2012;<span class="ref-vol">22</span>(1):1–8.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3246196/">PMC free article</a>]</span> [<a href="/pubmed/22147369" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genome+Res&amp;title=Rare+versus+common+variants+in+pharmacogenetics:+SLCO1B1+variation+and+methotrexate+disposition.&amp;author=LB+Ramsey&amp;author=GH+Bruun&amp;author=W+Yang&amp;volume=22&amp;issue=1&amp;publication_year=2012&amp;pages=1-8&amp;pmid=22147369&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="element-citation">French D, Yang W, Cheng C, et al.  Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">113</span>(19):4512–4520.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2680361/">PMC free article</a>]</span> [<a href="/pubmed/19066393" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Acquired+variation+outweighs+inherited+variation+in+whole+genome+analysis+of+methotrexate+polyglutamate+accumulation+in+leukemia.&amp;author=D+French&amp;author=W+Yang&amp;author=C+Cheng&amp;volume=113&amp;issue=19&amp;publication_year=2009&amp;pages=4512-4520&amp;pmid=19066393&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="element-citation">Kawedia JD, Liu C, Pei D, et al.  Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">119</span>(7):1658–1664.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3286344/">PMC free article</a>]</span> [<a href="/pubmed/22117041" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Dexamethasone+exposure+and+asparaginase+antibodies+affect+relapse+risk+in+acute+lymphoblastic+leukemia.&amp;author=JD+Kawedia&amp;author=C+Liu&amp;author=D+Pei&amp;volume=119&amp;issue=7&amp;publication_year=2012&amp;pages=1658-1664&amp;pmid=22117041&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24">24. <span class="element-citation">Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2007;<span class="ref-vol">6</span>(2):149–165.</span> [<a href="/pubmed/17268486" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Discov&amp;title=New+therapeutic+strategies+for+the+treatment+of+acute+lymphoblastic+leukaemia.&amp;author=CH+Pui&amp;author=S+Jeha&amp;volume=6&amp;issue=2&amp;publication_year=2007&amp;pages=149-165&amp;pmid=17268486&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25">25. <span class="element-citation">Den Boer ML, van Slegtenhorst M, De Menezes RX, et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. <span><span class="ref-journal">Lancet Oncol. </span>2009;<span class="ref-vol">10</span>(2):125–134.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2707020/">PMC free article</a>]</span> [<a href="/pubmed/19138562" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Oncol&amp;title=A+subtype+of+childhood+acute+lymphoblastic+leukaemia+with+poor+treatment+outcome:+a+genome-wide+classification+study.&amp;author=ML+Den+Boer&amp;author=M+van+Slegtenhorst&amp;author=RX+De+Menezes&amp;volume=10&amp;issue=2&amp;publication_year=2009&amp;pages=125-134&amp;pmid=19138562&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26">26. <span class="element-citation">Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>(2):691–698.</span> [<a href="/pubmed/20068112" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=The+cross-validated+adaptive+signature+design.&amp;author=B+Freidlin&amp;author=W+Jiang&amp;author=R+Simon&amp;volume=16&amp;issue=2&amp;publication_year=2010&amp;pages=691-698&amp;pmid=20068112&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27">27. <span class="element-citation">Zaza G, Cheok M, Yang W, et al.  Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>(5):1778–1785.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1895216/">PMC free article</a>]</span> [<a href="/pubmed/15905191" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Gene+expression+and+thioguanine+nucleotide+disposition+in+acute+lymphoblastic+leukemia+after+in+vivo+mercaptopurine+treatment.&amp;author=G+Zaza&amp;author=M+Cheok&amp;author=W+Yang&amp;volume=106&amp;issue=5&amp;publication_year=2005&amp;pages=1778-1785&amp;pmid=15905191&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28">28. <span class="element-citation">Holleman A, Cheok MH, den Boer ML, et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">351</span>(6):533–542.</span> [<a href="/pubmed/15295046" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Gene-expression+patterns+in+drug-resistant+acute+lymphoblastic+leukemia+cells+and+response+to+treatment.&amp;author=A+Holleman&amp;author=MH+Cheok&amp;author=ML+den+Boer&amp;volume=351&amp;issue=6&amp;publication_year=2004&amp;pages=533-542&amp;pmid=15295046&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29">29. <span class="element-citation">Heim S, Lage H. Transcriptome analysis of different multidrug-resistant gastric carcinoma cells. <span><span class="ref-journal">In Vivo. </span>2005;<span class="ref-vol">19</span>(3):583–590.</span> [<a href="/pubmed/15875780" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=In+Vivo&amp;title=Transcriptome+analysis+of+different+multidrug-resistant+gastric+carcinoma+cells.&amp;author=S+Heim&amp;author=H+Lage&amp;volume=19&amp;issue=3&amp;publication_year=2005&amp;pages=583-590&amp;pmid=15875780&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30">30. <span class="element-citation">Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. <span><span class="ref-journal">Biochem J. </span>2003;<span class="ref-vol">370</span>(Pt 1):1–18.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1223165/">PMC free article</a>]</span> [<a href="/pubmed/12444918" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+J&amp;title=PDE4+cAMP+phosphodiesterases:+modular+enzymes+that+orchestrate+signalling+cross-talk,+desensitization+and+compartmentalization.&amp;author=MD+Houslay&amp;author=DR+Adams&amp;volume=370&amp;issue=Pt+1&amp;publication_year=2003&amp;pages=1-18&amp;pmid=12444918&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31">31. <span class="element-citation">Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>(8):5493–5496.</span> [<a href="/pubmed/12493749" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Cyclic+AMP-specific+PDE4+phosphodiesterases+as+critical+components+of+cyclic+AMP+signaling.&amp;author=M+Conti&amp;author=W+Richter&amp;author=C+Mehats&amp;author=G+Livera&amp;author=JY+Park&amp;volume=278&amp;issue=8&amp;publication_year=2003&amp;pages=5493-5496&amp;pmid=12493749&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B32">32. <span class="element-citation">Smith PG, Wang F, Wilkinson KN, et al.  The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>(1):308–316.</span> [<a href="/pubmed/15331441" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The+phosphodiesterase+PDE4B+limits+cAMP-associated+PI3K/AKT-dependent+apoptosis+in+diffuse+large+B-cell+lymphoma.&amp;author=PG+Smith&amp;author=F+Wang&amp;author=KN+Wilkinson&amp;volume=105&amp;issue=1&amp;publication_year=2005&amp;pages=308-316&amp;pmid=15331441&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B33">33. <span class="element-citation">Meyers JA, Su DW, Lerner A. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. <span><span class="ref-journal">J Immunol. </span>2009;<span class="ref-vol">182</span>(9):5400–5411.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2676892/">PMC free article</a>]</span> [<a href="/pubmed/19380787" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol&amp;title=Chronic+lymphocytic+leukemia+and+B+and+T+cells+differ+in+their+response+to+cyclic+nucleotide+phosphodiesterase+inhibitors.&amp;author=JA+Meyers&amp;author=DW+Su&amp;author=A+Lerner&amp;volume=182&amp;issue=9&amp;publication_year=2009&amp;pages=5400-5411&amp;pmid=19380787&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B34">34. <span class="element-citation">Kim SW, Rai D, Aguiar RC. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma. <span><span class="ref-journal">Clin Cancer Res. </span>2011;<span class="ref-vol">17</span>(21):6723–6732.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4651210/">PMC free article</a>]</span> [<a href="/pubmed/21742807" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Gene+set+enrichment+analysis+unveils+the+mechanism+for+the+phosphodiesterase+4B+control+of+glucocorticoid+response+in+B-cell+lymphoma.&amp;author=SW+Kim&amp;author=D+Rai&amp;author=RC+Aguiar&amp;volume=17&amp;issue=21&amp;publication_year=2011&amp;pages=6723-6732&amp;pmid=21742807&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B35">35. <span class="element-citation">Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. <span><span class="ref-journal">Clin Cancer Res. </span>2007;<span class="ref-vol">13</span>(16):4920–4927.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2656255/">PMC free article</a>]</span> [<a href="/pubmed/17699872" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Phosphodiesterase+4+inhibitors+augment+levels+of+glucocorticoid+receptor+in+B+cell+chronic+lymphocytic+leukemia+but+not+in+normal+circulating+hematopoietic+cells.&amp;author=JA+Meyers&amp;author=J+Taverna&amp;author=J+Chaves&amp;author=A+Makkinje&amp;author=A+Lerner&amp;volume=13&amp;issue=16&amp;publication_year=2007&amp;pages=4920-4927&amp;pmid=17699872&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B36">36. <span class="element-citation">Ogawa R, Streiff MB, Bugayenko A, Kato GJ. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. <span><span class="ref-journal">Blood. </span>2002;<span class="ref-vol">99</span>(9):3390–3397.</span> [<a href="/pubmed/11964308" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Inhibition+of+PDE4+phosphodiesterase+activity+induces+growth+suppression,+apoptosis,+glucocorticoid+sensitivity,+p53,+and+p21(WAF1/CIP1)+proteins+in+human+acute+lymphoblastic+leukemia+cells.&amp;author=R+Ogawa&amp;author=MB+Streiff&amp;author=A+Bugayenko&amp;author=GJ+Kato&amp;volume=99&amp;issue=9&amp;publication_year=2002&amp;pages=3390-3397&amp;pmid=11964308&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B37">37. <span class="element-citation">Yates CR, Chang C, Kearbey JD, et al.  Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. <span><span class="ref-journal">Pharm Res. </span>2003;<span class="ref-vol">20</span>(11):1794–1803.</span> [<a href="/pubmed/14661924" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharm+Res&amp;title=Structural+determinants+of+P-glycoprotein-mediated+transport+of+glucocorticoids.&amp;author=CR+Yates&amp;author=C+Chang&amp;author=JD+Kearbey&amp;volume=20&amp;issue=11&amp;publication_year=2003&amp;pages=1794-1803&amp;pmid=14661924&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B38">38. <span class="element-citation">van Asperen J, van Tellingen O, Beijnen JH. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. <span><span class="ref-journal">Drug Metab Dispos. </span>2000;<span class="ref-vol">28</span>(3):264–267.</span> [<a href="/pubmed/10681369" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Metab+Dispos&amp;title=The+role+of+mdr1a+P-glycoprotein+in+the+biliary+and+intestinal+secretion+of+doxorubicin+and+vinblastine+in+mice.&amp;author=J+van+Asperen&amp;author=O+van+Tellingen&amp;author=JH+Beijnen&amp;volume=28&amp;issue=3&amp;publication_year=2000&amp;pages=264-267&amp;pmid=10681369&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B39">39. <span class="element-citation">Stanulla M, Schaffeler E, Arens S, et al.  GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Int J Hematol. </span>2005;<span class="ref-vol">81</span>(1):39–44.</span> [<a href="/pubmed/15717687" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Hematol&amp;title=GSTP1+and+MDR1+genotypes+and+central+nervous+system+relapse+in+childhood+acute+lymphoblastic+leukemia.&amp;author=M+Stanulla&amp;author=E+Schaffeler&amp;author=S+Arens&amp;volume=81&amp;issue=1&amp;publication_year=2005&amp;pages=39-44&amp;pmid=15717687&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B40">40. <span class="element-citation">Jamroziak K, Mlynarski W, Balcerczak E, et al.  Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Eur J Haematol. </span>2004;<span class="ref-vol">72</span>(5):314–321.</span> [<a href="/pubmed/15059065" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Haematol&amp;title=Functional+C3435T+polymorphism+of+MDR1+gene:+an+impact+on+genetic+susceptibility+and+clinical+outcome+of+childhood+acute+lymphoblastic+leukemia.&amp;author=K+Jamroziak&amp;author=W+Mlynarski&amp;author=E+Balcerczak&amp;volume=72&amp;issue=5&amp;publication_year=2004&amp;pages=314-321&amp;pmid=15059065&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3501717&amp;issue-id=216549&amp;journal-id=446&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140719317264656title">Abstract</a></li><li><a href="#__sec1title">Introduction</a></li><li><a href="#__sec2title">Methods</a></li><li><a href="#__sec11title">Results</a></li><li><a href="#__sec15title">Discussion</a></li><li><a href="#__sec16title">Supplementary Material</a></li><li><a href="#idm140719392304960title">Acknowledgments</a></li><li><a href="#idm140719318484624title">Footnotes</a></li><li><a href="#__sec17title">Authorship</a></li><li><a href="#idm140719392302496title">References</a></li></ul></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr>Articles from <span class="acknowledgment-journal-title">Blood</span> are provided here courtesy of <strong>The American Society of Hematology</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC3501717/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC3501717/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC3501717/?report=printable">Printer Friendly</a></li> | <li><a href="#" data-citationid="PMC3501717" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3501717%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3501717%2F&amp;text=Genome-wide%20association%20study%20identifies%20germline%20polymorphisms%20associated%20with%20relapse%20of%20childhood%20acute%20lymphoblastic%20leukemia" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3501717%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="23007406" data-aiid="3501717" data-aid="3501717" data-iid="216549" data-domainid="446" data-domain="blood" data-accid="PMC3501717" data-md5="6d41cad879d55ea978b5b6dcba4ca79d"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T09:37:06-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal105&amp;ncbi_phid=CE8C6F0DDD546C410000000006570434&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3501717%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=blood&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC3501717/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>